Caly Chien

发表

Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin

A. Bernard, N. Vaccaro, M. Acharya, 2015, Clinical pharmacology in drug development.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Nicholas A. Meanwell, Lawrence G. Hamann, 2010, Nature.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (B

N. Meanwell, D. Langley, R. Colonno, 2013, Journal of medicinal chemistry.

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer

S. Upadhyay, W. Figg, P. Mendiratta, 2018, The Journal of clinical investigation.

Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.

D. Grasela, P. Timmins, A. Dennis, 2013, Journal of pharmaceutical sciences.

Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes

F. Jacobs, J. Snoeys, R. de Vries, 2019, Drug Metabolism and Disposition.

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer

F. Saad, R. de Wit, W. Edenfield, 2018, Cancer Chemotherapy and Pharmacology.

Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study

N. Agarwal, O. Ackaert, S. Chowdhury, 2022, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

J. Carles, I. Durán, J. Jiao, 2020, Clinical Pharmacokinetics.

Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

E. Small, J. Pérez-Ruixo, D. Ouellet, 2020, Clinical Cancer Research.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model

M. Monshouwer, D. Ouellet, L. D. De Zwart, 2020, Clinical Pharmacokinetics.

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

J. Pérez-Ruixo, D. Ouellet, O. Ackaert, 2019, Clinical Pharmacokinetics.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Effect of food on abiraterone pharmacokinetics: a review

Caly Chien, M. Smith, Michael Smith, 2017 .